Status:
ACTIVE_NOT_RECRUITING
Fibroscan Study in HCC
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Confirmed Diagnosis of Hepatocellular Carcinoma
Patients Who Are Scheduled to Undergo Transarterial Chemobolization, Systemic Therapy Surgery
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
In patients with HCC undergoing therapy 1. We aim to determine the prognostic significance of liver stiffness in patients with HCC 2. We aim to determine the rate and severity of complications of trea...
Eligibility Criteria
Inclusion
- Clinical diagnosis of HCC
- Patients who are scheduled to undergo therapy, either TACE systemic therapy or surgery
- For TACE cohort, patients undergoing first cycle TACE are eligible.
- For systemic therapy cohort, patients undergoing first-line systemic therapy are eligible.
- For surgery cohort, patient undergoing surgery are eligible.
- Prior surgery or loco-ablative therapy (e.g. Radiofrequency ablation, microwave, percutaneous ethanol injection) is allowed
- Child's A to Child's C liver function
Exclusion
- ECOG performance status \> 2
- Poorly controlled ascites
Key Trial Info
Start Date :
February 27 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2027
Estimated Enrollment :
207 Patients enrolled
Trial Details
Trial ID
NCT01796145
Start Date
February 27 2013
End Date
December 31 2027
Last Update
November 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Clinical Oncology, Prince of Wales Hospital
Hong Kong, Hong Kong